Member Info for PM2022

I think Suzy had an 80 per cent record for a placing despite the downwards trend the

Share price did more than 10 bag after 3/6p placing i think when she started. Plus went from 10p to 20p but down again.

This time the CEO is heavily invested and easy to see why.

The analyst report by Shard Capital highlights that ValiRx has introduced a new service, Assay Ready Reagents, as part of its offerings. ValiRx recently acquired approximately 5,000 vials of PDCs at a significant discount. The initial sale on November 18th indicates an implied valuation exceeding £4 million, which is substantially higher than the company’s current valuation.

https://valirx.com/analyst-research see report 10 december 2024

Our share price experienced a significant decline prior to the last two placings. This, combined with previous delays related to sub-license 201, has resulted in the share price being substantially undervalued. This valuation does not yet reflect the potential of other pipeline compounds such as Val401, developments with Inophea Labs, an upcoming SPV announcement, and additional project work that has yet to be factored in.

It is my view that we will comfortably multibag this year if we can secure one of the anticipated deals shortly. I also feel with no equity raise expected for 2025 that some of our assets will start to value will start to price into the market cap. I am confident we can get to 5, 10p or more but that would be dependent on outcomes.

Our CEO owns 6% of the company purchased recently which adds to the confidence at such a low market cap.

See the recent interview by our CEO and momentum is likely to start shortly.

Https://www.proactiveinvestors.co.uk/companies/news/1064075/valirx-advances-women-s-health-and-oncology-pipeline-with-focus-on-triple-negative-breast-cancer-1064075.html

As always best not to follow anyone and do your own research . We have a few here that have lost money in the past like many others and a few that have lost a on stocks like 4D. I'll post why I am confident but just my views as to why this is such a fantastic buy at the moment. Note those not invested are here for a reason.

ValiRx previously reached highs of 74p and 64p with approximately 65 million shares in circulation, driven by the positive results of the 201 clinical trial and the execution of a letter of intent. However, the share price declined due to the inability of TRX to raise cash at that time and further dropped because of subsequent funding delays. Currently, the number of shares has increased by about fivefold from that . It now appears that TRX is finalising the 201 deal, which requires a Nasdaq listing to provide investors with an exit strategy and to raise additional funds for trials. The completion of the 201 sublicense agreement, expected before end of May 2025, will grant ValiRx the owed funds (a significant amount relative to the market cap) and a 0.5% equity stake also likely to be very valuable. The deal includes payments of about 2 million and 61 million milestone payments .

At its previous highs, ValiRx did not yet possess its most valuable asset, CLX001. This compound has successfully passed the evaluation stage, demonstrating extensive in vitro testing, proven in vivo efficacy, and safety. It has also undergone lead freeze-dried nanoformulation development, a critical phase in preclinical testing. Furthermore, CLX001 has shown potential against other cancers, such as prostate cancer. Please see below and previous RNSs:

https://valirx.com/clx001

The valuation could already be as high as £10/£20 million for CLX001 given the amount of work done and the novel nature of this compound. Over the coming months, CLX001 will likely undergo toxicology testing, which, if successful, is expected to significantly increase the compound’s value and bring it closer to the partnering stage. While the drug's potential has yet to be fully reflected in the share price, the scientific results to date have been highly promising.

As updates are released, the share price is likely to start factoring in the value of CLX001, with the company’s valuation likely increasing by many millions. Preclinical upfront payments typically average around £40 million, with milestone payments reaching hundreds of millions. While earlier-stage deals are possible, they tend to come with lower payments. (please see broker report from Shard)

For VAL401, we were informed that only one clinical trial is required . With potential milestones valued at £16 million for this deal, it becomes a highly valuable asset for the company. At the current market cap of £2 million, coupled with cash reserves secured for 2025, we are significantly undervalued. Achieving these milestones is likely to attract larger investments from institutional investors

Porky knows nothing. I asked him a basic question but he did not know the answer. He talks rubbish.

If they deliver a deal the shares at these prices will get washed away in no time at all. Even a small buy gets your millions of shares .

It demonstrates that we are massively undervalued. What you see is not what something is really worth. My perceived valuation remains the same.

With penny stocks they could be pumped to 100 million based on nonsense. The same reversal applies.

Anyway don't divert from my question to Porky. Not interested in your thoughts.

How about this since you know so much. Before I post please confirm what Valirx has done with CLX and all the stages etc?

Let me see how much you know. Please demonstrate your knowledge to us all?

I await your response since you seem to know it all?

You can say the same about every company and asset. Nobody is stupid enough to fall for that nonsense. You recently purchased GDR i don't see contracts in the 10s millions coming through. In fact losing millions every year but potential is factored in otherwise why would you have invested.

They have LOI and a merger with a Nasdaq company and as stated in the presentation the terms of the LOI will not change if anything Valirx have gained even more with the 0.5% equity on top of the 2 million and 61 million. That sounds like it has significant value to me.

As I say nobody is going to fall for your nonsense.

2 million is far less than the 55 million 4D were burning and any other biotech that has any real value. The market cap should go above 10/20 million this year with cash in the bank.

I'll post my views tomorrow but one thing I know is to not listen to you as you have an agenda and twist the real facts. The difference between us and you is that we are invested so we post what we think whereas you have an agenda to force people to sell for your own benefit.

I'll respond tomorrow as not been on my computer.

Either he is trying to force people to sell so he can buy below placing price or is just jealous. Why else would he be here.

Those that follow him will be watching whilst he secretly executes his trade and makes money.

I think both 201 and 401 will get signed so yes. I also think significant CLX news will be released before then plus SPV so we could be 2/3p before any deal. Don't forget if the merger completes as expected we will likely rise massively before the deal and again after the deal.

Previously i think we went from 3p to 74p in a few weeks but that was just on 201 alone.

No logic to spending so much time and money with all resources they put in to just fail now. In my view I think they have already raised the cash.

As stated towards the end of the interview.

News after news on the way in the coming weeks. Will we hit 2p, 5p, 10p or much more. Interesting times given our tiny market cap and huge potential.

Fully funded for 2025 as stated in the broker report.

I hope those quick 10 likes confirm what I just told you. You been fooled once again.

Doughnut paradise.

System bug, fake likes. Again don't be fooled. It was demonstrated in Telegram as one of the accounts has a bug that can do unlimited likes.

Guys don't be fooled. I think he is working for someone to make people sell so they can buy below placing price.

It's all garbage from him. Keep your shares and buy more if you so wish. Don't let them stop you. They will make money whilst you lose.

Smart strategy to target the US market. At this tiny market cap not much is needed to move this. When 201 gets done then amplify in the US release articles and interviews in the US and get buyers over. What is said here will make no difference.

Seems positive about 201 and CLX.

Waste of time arguing with him. He should know once Valirx get a few positive outcomes even if it was a few decent lab contracts and some progress on CLX then they can bring institutional investors in and get the price up if it remains low. At this low market cap it does not take much buying. A complete waste of energy from him. He will end up having a heart attack eventually. The placing showed they can and would invest as they see upside potential.

Most shareholders sold due to placing fears. 6p was dirt cheap and also a false down due to a leak prior to the previous 6p placing. We ended up at just over 1p then placing at 0.65p this time. Clearly a false down and not the true value of the company.

We should be 10p at the moment. With no placing and lots of significant outcomes due over the coming months we will relate.

With the new 201 IP it will be worth far more than you can imagine. This is the reason why TheoremRX was chosen.

CLX is likely worth more than 10 times our market cap due to the work already done. The lab is worth over 4 million with significant contracts coming our way . New SPV will have value and 201 and 401 deals will carry significant value the stages they are at is where the asset value will be and potential deals.

Our assets are worth far more than 1 million.

Sometimes, you have to play role of the fool to fool the fool who thinks they are fooling you.

No they prioritise themselves over us so we follow they win and we win. The clue is in the big buys by the CEO and close associates including warrants low market cap, deals lined up.

False down back to fair value 10/15p plus in 2025.

If TRX raised the cash then the merger is highly likely to be successful.

This final extension has been provided following developments announced by TheoremRx regarding a transaction with a NASDAQ listed company which the board at ValiRx believe may lead to a positive conclusion for the proposed sub-license of VAL201.

Must be a reason why the CEO went all in and for the comment above. The City boys probably heard a rumour, who knows but I think 201 will get done. Why waste time doing legal work to get 0.5% equity if it was likely to fail.

If 201 completes then this could hit 6-10p with other news also helping push the price up. We also have an insurance with 401 and CLX if it does fail so not a bad buy here.

CLX0001 toxicology results over the coming months could alone take this to 5-10p range. Talks of CLX already being worth 20 million.

Given positive data so far in vitro, in vivo, formulation now toxicology results will get close to deal stage ready with talks of at least 40 million upfront and 800 milestone payments. Toxicology results will be very significant to the market cap and should price the compound where it should be.

Val201 - We have been to 65p and 74p because of that due to conclude by May 2025. I would give this a decent chance of getting over the line. I suspect funding has been successful.

Val401- Deal also due to conclude in the coming weeks/months.

New SPV- 3 outcomes due expecting at least one to be taken on. Worth at least a few million to the market cap.

Lab revenue- Talks of the lab being worth over 4 million. Lots of contracts to be announced.

With no news so far the real fun will start once the newsflow starts coming. The CEO purchased a large amount because clearly we are undervalued, oversold and this should bounce big in the coming weeks.